Tamara K. Moyo

Tamara K. Moyo

Hematology | Oncology

1021 Morehead Medical Drive
Building 2, Suite 60201
Charlotte, NC 28204

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Journal: Blood cancer journal

Published: December 12, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances

Published: September 24, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances

Published: September 24, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Journal: Blood advances

Published: September 24, 2025

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Journal: Blood

Published: September 02, 2025

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Journal: Cancers

Published: May 28, 2025

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Journal: Blood advances

Published: May 09, 2025

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Journal: Blood advances

Published: April 24, 2025

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Journal: Blood cancer journal

Published: November 25, 2024

Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice.

Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice.

Journal: JCO oncology practice

Published: November 18, 2024

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.

Journal: Blood cancer journal

Published: September 03, 2024

Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.

Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: April 29, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026